# ZR-MTX for PIOL Phase II Trial

> **NCT06973811** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 47 (estimated)

## Conditions studied

- Primary Intraocular Lymphoma

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Rituximab (R)
- **DRUG:** Zanubrutinib
- **DRUG:** Methotrexate (MTX)

## Key facts

- **NCT ID:** NCT06973811
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-10
- **Primary completion:** 2027-10-30
- **Final completion:** 2029-10-30
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2025-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06973811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06973811, "ZR-MTX for PIOL Phase II Trial". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06973811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*